Human resources software startup Factorial has raised $150 million in funding at a valuation of $2.5 billion, making it one of the most highly valued startups in Spain. The Series D funding round was ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

General Catalyst leads $150M equity investment, its first equity stake in Factorial as part of Series D round that values the company at over $2.5 billion, becoming one of the most valuable AI ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

BARCELONA—Factorial closed a $150 million funding round that lifted its valuation to $2.5 billion, bringing in fresh capital to expand as artificial intelligence reshapes the business-management ...

Executive function describes a set of cognitive processes and mental skills that help an individual plan, monitor, and successfully execute their goals. The “executive functions,” as they’re known, ...

As Billerica battery company Factorial cruises into the public markets this week, it will have a veteran driver at its side: “Dr. Z.” Dieter Zetsche, one of the best-known executives in the car ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.